Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials

Hypoxia-activated prodrugs (HAPs) are designed to specifically target the hypoxic cells of tumors, which are an important cause of treatment resistance to conventional therapies. Despite promising preclinical and clinical phase I and II results, the most important of which are described in this revi...

Descripción completa

Detalles Bibliográficos
Autores principales: Spiegelberg, Linda, Houben, Ruud, Niemans, Raymon, de Ruysscher, Dirk, Yaromina, Ala, Theys, Jan, Guise, Christopher P., Smaill, Jeffrey B., Patterson, Adam V., Lambin, Philippe, Dubois, Ludwig J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357685/
https://www.ncbi.nlm.nih.gov/pubmed/30734002
http://dx.doi.org/10.1016/j.ctro.2019.01.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357685/
https://www.ncbi.nlm.nih.gov/pubmed/30734002
http://dx.doi.org/10.1016/j.ctro.2019.01.005

Ejemplares similares